Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.
The 7th Neuropsychiatric Drug Development Summit returns as the industry’s only end-to-end gathering, dedicated to innovating precision psychiatry and propelling next-generation drug R&D. Uniting discovery, preclinical, clinical, regulatory, and commercial experts to address the field’s most pressing challenges, join 3-days of forward-thinking discussions and stay up-to-date with new targets, mechanisms, and technologies transforming the mental health treatment landscape.
September 24-26, 2024, Boston, MA
Prop. 122, which called for the creation of a regulated natural medicine (psychedelics) system in Colorado, didn’t permit localities to opt-out, unlike Oregon’s Measure 109. But, locals are finding a way by setting time, place and manner restrictions.
J&J has filed a supplemental NDA (sNDA) with FDA, Seeking Approval of Spravato as a monotherapy for Treatment-Resistant Depression. If approved, the esketamine nasal spray would become the first monotherapy for adults with the depressive disorder.
See also DEA’s Move To Ban Two Psychedelics Is Challenged As A ‘Disservice To Science’ In Legal Filing From Student Group (July 24) ↗ Marijuana Moment.
Coverage of Siegel et al.’s new study, Psilocybin desynchronizes the human brain, published in Nature on Wednesday. The paper was widely covered elsewhere, including in The New York Times.
“…the top deck of the Semel Institute is being reimagined as a state-of-the-art living laboratory to study Ecological Medicine and psychedelic therapies. It will be the first of its kind in a biomedical setting.”
See the CDC’s study of such products here.
Vicente LLP walk us through more than a dozen hearings, meetings and (proposed) rule updates since our last Bulletin. As we head into a month that features final public hearings on a number of matters, now is the time to make your voice heard.
The BBC looks at what happened to Awakn’s Bristol clinic. TL;DR: There weren’t enough patients able or willing to afford the out-of-pocket costs for treatment courses.
In this Issue:
Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.